We are pleased to announce that the acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners has been completed. Read the Press Release
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for gene and cell therapy professionals. The meeting is the best place for people in the field to learn from the latest scientific research, stay current on new technologies, and make career-advancing connections with peers. Booth #237
The Pharma Manufacturing World Summit is a premier gathering of industry leaders, pharmaceutical manufacturing executives, and experts dedicated to exploring innovative strategies, emerging trends, and best practices in the dynamic world of pharmaceutical management.
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geographic reach London, UK, […]
Read moreAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and […]
Read moreTUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with […]
Read moreTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) today announced they have entered into a definitive merger […]
Read moreTUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, and Pramthesh […]
Read moreTUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers of […]
Read more© 2025 Avid Bioservices, Inc. All rights reserved.
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
Notifications
